Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone

ABSTRACT Importance Recombinant human growth hormone (rhGH) improves height in children with growth hormone deficiency (GHD). However, its metabolic effects remain unclear. Objective To synthesize evidence regarding the metabolic effects of rhGH or growth hormone (GH) derivatives in GHD, identify knowledge gaps, and highlight future research priorities. Methods PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang databases were searched in July 2023 to identify studies on metabolic effects of GH treatment. Bubble plots were used to visualize GH treatment effects on metabolic parameters according to treatment duration by comparison with baselines, nonpharmacological interventions, and healthy controls. Random‐effects meta‐analyses were conducted for outcomes with inconsistent findings across original studies when randomized controlled trial data were sufficient. The study was registered with INPLASY (INPLASY202450064). Results Sixty‐three studies (6158 participants) analyzed the effects of GH treatment on metabolic outcomes in children with GHD. Overall, GH treatment slightly affected glucose levels; lipid effects were inconsistent. GH treatment did not influence bone mineral density, bone mineral content, or parathyroid hormone levels. Most studies showed no significant effects on thyroid hormone levels, body composition, or body mass index (BMI). GH treatment may increase serum asymmetric dimethylarginine and gastrin levels while reducing tumor necrosis factor and serum urea levels. Interpretation Glucose and thyroid outcomes are consistent with clinical observations; effects on lipids, calcium, phosphorus, body composition, BMI, and waist‐to‐hip ratio require further validation owing to data inconsistency. New biomarkers are warranted. Further clinical studies are needed in children across age groups, GHD severities, and nutritional statuses.

Authors

Institutions

Publication Details

Journal
Pediatric Investigation
Published
2026-03-11
DOI
https://doi.org/10.1002/ped4.70050
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone

You Wu, Yuning Zhao, Yue Zhao, Ningyi Song et al.
Pediatric Investigation
Growth Hormone and Insulin-like Growth Factors
article

Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone

You Wu, Yuning Zhao, Yue Zhao, Ningyi Song, Xiao Luo, Wei Wu, Caiqi Du
article en

Abstract

ABSTRACT Importance Recombinant human growth hormone (rhGH) improves height in children with growth hormone deficiency (GHD). However, its metabolic effects remain unclear. Objective To synthesize evidence regarding the metabolic effects of rhGH or growth hormone (GH) derivatives in GHD, identify knowledge gaps, and highlight future research priorities. Methods PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang databases were searched in July 2023 to identify studies on metabolic effects of GH treatment. Bubble plots were used to visualize GH treatment effects on metabolic parameters according to treatment duration by comparison with baselines, nonpharmacological interventions, and healthy controls. Random‐effects meta‐analyses were conducted for outcomes with inconsistent findings across original studies when randomized controlled trial data were sufficient. The study was registered with INPLASY (INPLASY202450064). Results Sixty‐three studies (6158 participants) analyzed the effects of GH treatment on metabolic outcomes in children with GHD. Overall, GH treatment slightly affected glucose levels; lipid effects were inconsistent. GH treatment did not influence bone mineral density, bone mineral content, or parathyroid hormone levels. Most studies showed no significant effects on thyroid hormone levels, body composition, or body mass index (BMI). GH treatment may increase serum asymmetric dimethylarginine and gastrin levels while reducing tumor necrosis factor and serum urea levels. Interpretation Glucose and thyroid outcomes are consistent with clinical observations; effects on lipids, calcium, phosphorus, body composition, BMI, and waist‐to‐hip ratio require further validation owing to data inconsistency. New biomarkers are warranted. Further clinical studies are needed in children across age groups, GHD severities, and nutritional statuses.

Pediatric Investigation
Novo Nordisk (Switzerland) (CH), Tongji Hospital (CN), Union Hospital (CN), Huazhong University of Science and Technology (CN)
Industry, innovation and infrastructure
Openalex Percentile: Top 27%
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.